A prospective, single centre, open label, single arm pilot study to ...
Amlapitta Mishran significantly reduced endoscopic gastritis symptoms and scores in a 30-day study with 28 participants. Endoscopy and symptom scores improved notably, with 64% showing no erosions and over 89% experiencing ≥50% symptom improvement. Safety assessments remained normal throughout.
Reference News
A prospective, single centre, open label, single arm pilot study to ...
Amlapitta Mishran significantly reduced endoscopic gastritis symptoms and scores in a 30-day study with 28 participants. Endoscopy and symptom scores improved notably, with 64% showing no erosions and over 89% experiencing ≥50% symptom improvement. Safety assessments remained normal throughout.